Calcipotriol nanosuspension

A technology of suspension and calcipotriol monohydrate, which is applied in the field of nanocrystal suspension, can solve problems such as aggravating inflammatory response

Inactive Publication Date: 2018-11-30
JIANGSU SEMPOLL PHARMA
View PDF20 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For this reason, the presence of propylene glycol as a solvent in compositions intended to treat inflammatory skin diseases may exacerbate the inflammatory response

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Calcipotriol nanosuspension

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0050] The present suspension may contain non-ionic, polymeric surfactants, especially isopropyl oleate, which are added to better prevent aggregation of nanocrystals of calcipotriol and / or to prevent crystal growth. The surfactant should preferably be one that does not cause any significant solubilization of the calcipotriol monohydrate nanocrystals, i.e. it should have poor solubilizing power, and may advantageously be selected from poloxamer Or polysorbate surfactant, and polyoxyethylene C6-24 alkyl ether. The poloxamer may be selected from poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338 and poloxamer 407. In particular, it has been found that Poloxamer 188 has poor solubilizing power for solubilizing calcipotriol and thus serves as the currently favored surfactant for the present nanosuspensions. When polysorbate is used as the surfactant, it may be selected from polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 61, polysorbate 80 and polysorbate 81. ...

Embodiment 1

[0141] Preparation of Calcipotriol Monohydrate Nanocrystals

[0142] 4 g of Poloxamer 188 and 4 g of isopropyl oleate were dissolved in 196 ml of laboratory water while stirring, and an appropriate amount of NaOH was added to adjust the pH to 8.5.

[0143] Weigh 3.5g of 2mm glass spheres into a vial fitted with a screw cap. 0.035 g of calcipotriol monohydrate was added to each vial, followed by 1.05 g of a solution of 2% poloxamer 188 and 2% isopropyl oleate was added to each vial. Calcipotriol monohydrate was ground by shaking on an orbital shaker at 2000 rpm.

[0144] After grinding, the vial and glass ball used for grinding were washed with 24.0 g of laboratory water pH 8.5, and the suspension of calcipotriol monohydrate was poured into a blue cap bottle. The suspension was transferred to an Emulsiflex C3 (Avestin) high pressure homogenizer and the blue cap bottle was washed with 4.9 g of laboratory water pH 8.5. High pressure homogenization was carried out at 500 bar fo...

Embodiment 2

[0146] Ointment Containing Calcipotriol Monohydrate Nanocrystals

[0147] An ointment of the composition shown in Table 1-1 below is prepared by mixing the components of the lipid phase (hydrocarbons + polyoxyethylene-2-stearyl ether + α-tocopherol) under heating to 80-85° C. + isopropyl oleate). Disodium edetate and disodium hydrogen phosphate dihydrate were dissolved in an appropriate amount of calcipotriol monohydrate nanosuspension adjusted to contain 50 μg / g calcipotriol monohydrate (as in Example 1) to prepare the aqueous phase. With stirring and heating to 35-40 °C, glycerol was added to the suspension and the pH of the mixture was adjusted to 8.5 with 1N HCl or NaOH as needed.

[0148] Add the aqueous phase to the lipid phase and stir for 30 minutes. After that, the obtained ointment was cooled slowly to below 32°C, packed into aluminum tubes and stored at room temperature.

[0149] Composition (mg / g)

[0150] Evaluation of the suspension

[0151]

[0...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to view more

Abstract

The invention discloses a suspension of calcipotriol monohydrate in a nanocrystal form, wherein the particle size, measured through dynamic light scattering, of crystals of the calcipotriol monohydrate is distributed within the range of 200-600 nm. The suspension includes a water phase. The water phase comprises quantitative nonionic and polymeric surfactants and isopropyl oleate which sufficiently prevent forming of calcipotriol monohydrate nanocrystal aggregates and/or crystal growing. The calcipotriol in the suspension has good skin penetrability and biological activity, and has good stability characteristic.

Description

【Field of Invention】 [0001] The present invention relates to suspensions of calcipotriol monohydrate in the form of nanocrystals and to said nanocrystal suspensions for inclusion in pharmaceutical compositions intended for the prevention or treatment of skin diseases and disorders. 【Background of the invention】 [0002] Psoriasis is a chronic inflammatory skin disorder characterized by erythematous, dry, scaly plaques due to epidermal keratosis. Plaques are most commonly found on the elbows, knees, and scalp, although more lesions may appear on other parts of the body, especially the lumbosacral region. The most common treatment of mild to moderate psoriasis involves topical application of compositions containing corticosteroids as active ingredients. Although effective, corticosteroids have the disadvantage of numerous side effects such as skin atrophy, striae, acneiform rash, perioral dermatitis, dermatophytic and bacterial overgrowth, hypopigmented skin pigmentation, a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/10A61K9/06A61K31/593A61K47/14A61K47/10A61K47/26A61P17/06A61P17/10A61P31/10A61P17/08
CPCA61K9/0014A61K9/06A61K9/10A61K31/593A61K47/10A61K47/14A61K47/26A61P17/06A61P17/08A61P17/10A61P31/10
Inventor 沈媛媛陈桔英鲍丰祺
Owner JIANGSU SEMPOLL PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap